BioSpace News Archive

Due to its large size a biopharmaceutical generally exhibits complex three-dimensional higher-order structures (HOS) which are important factors in the protein’s biological function and activity – and thus essential for the therapeutic’s in-vivo efficiency and safety.

A team consisting of Keck Graduate Institute (KGI) Professor Jim Sterling, Western University Professor Lyna Luo, and postdoctoral scientists Wenjuan Jiang and Wesley Botello-Smith have discovered important physical mechanisms that cell surfaces utilize to provide innate immunity.

Only a few crop protection products have stood the test of time as increasing regulations, resistant pests, and grower preferences have changed over the years. Yet DiPel® Biological Insecticide stands alone as the leading lepidopteran biological control product growers have depended upon for 50 years.

Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the Cue COVID-19 Test for Home and Over The Counter (OTC) Use.

AbCellera (Nasdaq: ABCL) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive scientific opinion for bamlanivimab alone and bamlanivimab administered together with etesevimab

Apellis Pharmaceuticals, Inc., a global biopharmaceutical company and leader in targeted C3 therapies, announced that the company approved the grant of equity awards to two new employees with grant date of March 1, 2021, as equity inducement awards outside of the company’s 2017 Stock Incentive Plan and material to the employees’ acceptance of employment with the company.

G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for an aggregate of 14,300 shares of G1’s common stock to two employees under the G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan (the “Inducement Plan”).

ViewRay, Inc. (NASDAQ: VRAY) (the “Company”) today announced that members of management will be participating in the 21st Annual Oppenheimer Healthcare Conference on Tuesday, March 16, 2021

Adamas Pharmaceuticals, Inc. announced that the compensation committee of the company’s board of directors granted two new employees restricted stock units to acquire 57,000 shares of the company’s common stock.

Cue Health Inc. (Cue) announced the healthcare technology company has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for over the counter sale of its fast, accurate, COVID-19 test, making it the nation’s first molecular diagnostic test available to consumers without a prescription.